Figure 5. Pharmacologic inhibition of PGE₂-signaling in combination with IM treatment leads to reduction of LSCs in a serial BM transplantation assay in vivo.

(A) Treatment schedule of secondary recipient mice (n ≥ 8 mice/cohort) injected with 150,000 GFP⁺Sca-1⁺ cells out of primary recipient mice. (B) Representative analysis plot of GFP⁺Lin^- and GFP⁺LSK compartments of secondary recipient mice after treatment. (C) Co-treatment of secondary recipient mice with IM and indomethacin leads to reduction of GFP⁺Lin^- cells (p=.0635) and to significant depletion of GFP⁺LSK cells (p=.0159) in the BM. GFP⁺Lin^- cells were reduced from 42,560 (IM only group) to 9,867 (IM+INDO treated cohort). This translated into a significant reduction of GFP⁺LSK cells from 823 to 146, respectively. (Error bars indicate SD of GFP positive cells; n>4 per cohort investigated). Evaluation of secondary recipients after drug combination therapy is displayed in Supplemental Figure S4.